AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Advanced Metastatic Breast Cancer Clinical Trial

Official title:
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant

Clinical Trial Description

A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination with Intramuscular (IM) Fulvestrant to Patients with Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer. ;

Study Design

Related Conditions & MeSH terms

Advanced Metastatic Breast Cancer
Breast Neoplasms

Clinical Trial Details

NCT number	NCT01597388
Study type	Interventional
Source	AstraZeneca
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	May 8, 2012
Completion date	September 5, 2028

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03096847` - Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer	Phase 3
	Completed	`NCT02278120` - Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer	Phase 3